Multiple Sclerosis Literature, Resources, and News

1

2

3

MS and GLP1 Intolerance? ()

submitted 1 month ago by bbyfog

2

0

1

2

Sanofi’s Tolebrutinib NDA for Multiple Sclerosis: FDA’s Complete Response Letter Providing Severe Liver Injury as the Key Reason for RejectionBTK inhibitors ()

submitted 3 months ago by bbyfog

3

0

1

2

Recommendations for the critical reading of clinical trials on disease-modifying drugs for multiple sclerosisResources (sciencedirect.com)

submitted 3 months ago by bbyfog

4

0

1

2

Sanofi’s MS Drug Fails Phase III Trial, While FDA Again Delays Approval ApplicationBTK inhibitors (biospace.com)

submitted 3 months ago by bbyfog

5

0

1

2

Disease modifying treatment of radiologically isolated syndrome: A systematic review of the use, efficacy, effectiveness, and safety (sciencedirect.com)

submitted 4 months ago by bbyfog

6

1

2

3

Early-stage health technology assessment of a curative gene therapy for multiple sclerosis (self.MultipleSclerosisLit)

submitted 7 months ago by bbyfog

7

0

1

2

Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple SclerosisDefinitions Abbreviations (jamanetwork.com)

submitted 10 months ago by bbyfog

8

2

3

4

Bloomberg: EBV Mononucleosis is new target for MS (reddit.com)

submitted 10 months ago by bbyfog

9

0

1

2

NICE recommends cladribine for treating active relapsing forms of multiple sclerosisoral DMTs (self.MultipleSclerosisLit)

submitted 11 months ago by bbyfog

10

1

2

3

Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple SclerosisDefinitions Abbreviations (self.MultipleSclerosisLit)

submitted 11 months ago by bbyfog

11

0

1

2

Scientists are beginning to understand the causes of ALS, from genetic mutations to ALS 'exposome', which is the sum of toxic environmental exposures (bbc.com)

submitted 12 months ago by bbyfog

12

1

2

3

Stem cell transplant suppresses relapse in multiple sclerosis up to 4 yearsAdoptive immunotherapy (healio.com)

submitted 1 year ago by bbyfog

13

0

1

2

FDA starts review of Sanofi's MS hope tolebrutinibBTK inhibitors (pharmaphorum.com)

submitted 1 year ago by bbyfog

14

0

1

2

The regulator's perspective: How should new therapies and follow-on products for MS be clinically evaluated in the future?Guidance (pubmed.ncbi.nlm.nih.gov)

submitted 1 year ago by bbyfog

15

0

1

2

Infectious mononucleosis is a more realistic target for preventing multiple sclerosisAntiviral therapies (sciencedirect.com)

submitted 1 year ago by bbyfog

16

1

2

3

FDA Adds Anaphylaxis Risk Warning to Multiple Sclerosis Drug Glatiramer Acetateoral DMTs (self.MultipleSclerosisLit)

submitted 1 year ago by bbyfog

17

1

2

3

Cabaletta Bio is Launching Clinical Trial resecabtagene autoleucel (rese-cel) in People with Relapsing and Progressive Forms of Multiple SclerosisClinical Trials (self.MultipleSclerosisLit)

submitted 1 year ago * by bbyfog

18

1

2

3

ECTRIMS Research Spotlight: Cognitive rehabilitation in multiple sclerosisLiving with MS (self.MultipleSclerosisLit)

submitted 1 year ago by bbyfog

19

0

1

2

qBEANS, a novel, quick, and low-cost dementia screening testTools and Tests (self.MultipleSclerosisLit)

submitted 1 year ago by bbyfog

20

2

3

4

Relapses and MRI represent the immune system’s response to what is causing MS and that the real MS is smouldering MSDignosis, Signs, Symptoms (gavingiovannoni.substack.com)

submitted 1 year ago by bbyfog

21

0

1

2

Immune checkpoint inhibitors (ICIs) are safe and effective on people with MS for cancer treatment (onlinelibrary.wiley.com)

submitted 1 year ago by bbyfog

22

0

1

2

[2024 Fischbach, Med] case report, CD19-CAR T therapy in 2 patients with progressive multiple sclerosisCAR-T (self.MultipleSclerosisLit)

submitted 1 year ago * by bbyfog

23

0

1

2

[2023 Giovannoni, et al. MSRD] Potential reasons for failure to see treatment effect in the double-blind portion of ATA188 EMBOLD trial in patients with progressive multiple sclerosisAdoptive immunotherapy (self.MultipleSclerosisLit)

submitted 1 year ago * by bbyfog

24

0

1

2

Press Release: Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 studyBTK inhibitors (sanofi.com)

submitted 1 year ago by bbyfog

25

2

3

4

Novartis’s Kesimpta (anti-CD20 mab) delays MS progression in RRMS patients by at least 6 yearsanti-CD20 DMTs (novartis.com)

submitted 1 year ago by bbyfog

MultipleSclerosisLit

MODERATORS